Despite β-lactamase inhibitors being available for clinical use for nearly 30 years, a paucity
of data exists describing the pharmacokinetic-pharmacodynamic (PK-PD) determinants of …

We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index
best associated with the efficacy of tazobactam when used in combination with ceftolozane …

We recently investigated the pharmacokinetics-pharmacodynamics (PK-PD) of tazobactam
in combination with ceftolozane against an isogenic CTX-M-15-producing Escherichia coli …

We previously demonstrated that for tazobactam administered in combination with
ceftolozane, the pharmacokinetic-pharmacodynamic (PK-PD) index that best described …

The percentage of the time that the free drug concentration remains above a concentration
threshold (% fT> concentration threshold) has frequently been identified to be the optimal …

Ceftolozane plus tazobactam is an antipseudomonal cephalosporin combined with
tazobactam, an established beta-lactamase inhibitor, and has in vitro potency against a …

Ceftolozane/tazobactam is a novel antipseudomonal β‐lactam/β‐lactamase inhibitor
combination that is currently approved by the United States Food and Drug Administration …

Ceftolozane is a novel cephalosporin currently being developed with the β-lactamase
inhibitor tazobactam for the treatment of complicated urinary tract infections (cUTIs) …

Piperacillin-tazobactam has been proposed as an alternative to carbapenems for the
treatment of infections caused by extended-spectrum-β-lactamase (ESBL)-producing …

Pharmacokinetic–pharmacodynamic (PK–PD) modelling was used to study the impact of the
pharmacokinetics of tazobactam on the antimicrobial effect of piperacillin–tazobactam …